Clinical trials: Liver Tumor
Carcinoma, Hepatocellular
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular…
- Trial name
- RELATIVITY-106 (NCT05337137)
- Testing
- Relatlimab, Nivolumab, Bevacizumab
- Where
- 61 sites in United States, Australia and 13 more
- Volunteers
- 82 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumor
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
This was an open-label, Phase 1/2, dose escalation and signal finding study of derazantinib administered to patients with advanced solid tumors (Part 1; Dose Escalation/Food-effect Cohorts) or with advanced solid tumors with FGFR…
- Trial name
- NCT01752920
- Testing
- Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose range
- Where
- 12 sites in United States, Italy
- Volunteers
- 119 people
- Sponsor
- Basilea Pharmaceutica
Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC)
A Phase 1 Study of the Safety and Tolerability of CTX-10726
This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies.
- Conditions
- Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC)
- Trial name
- NCT07419841
- Testing
- CTX-10726
- Where
- 8 sites in United States
- Volunteers
- 70 people
- Sponsor
- Compass Therapeutics
Hepatocellular Carcinoma, Hepatocellular Cancer
Characterization of Methylation Patterns in Hepatocellular Carcinoma
This study is being performed as part of the development process of the Liver EpiCheck test which includes the identification of different methylation profiles in HCC (hepatocellular carcinoma) patients compare to cancer free…
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Cirrhosis
- Trial name
- NCT04264754
- Testing
- Blood collection
- Where
- 5 sites in Israel
- Volunteers
- 120 people
- Sponsor
- Nucleix Ltd.
Hepatocellular Carcinoma (HCC)
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
An Open-label, Multicenter, Phase II Clinical Study of AK104/AK112 in Combination with TT-00420 Tablet in Patients with Advanced Hepatocellular Carcinoma(HCC).
- Trial name
- NCT07052253
- Testing
- TT-00420 (tinengotinib), AK104, AK112
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Akeso
Solid Tumor Malignancies, Cancer, Solid Cancers
A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
A Phase I, open-label, first-in-human study to determine the MTD, recommended phase 2 dose (RP2D), assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of LXP1788 Injection in patients with…
- Conditions
- Solid Tumor Malignancies, Cancer, Solid Cancers, Solid Tumor Cancer, Solid Tumor, Unspecified, Adult
- Trial name
- NCT06883539
- Testing
- LXP1788 is administered intravenously via Port-A
- Where
- 2 sites in Taiwan
- Volunteers
- 24 people
- Sponsor
- LaunXP Biomedical Co., Ltd.
Hepatocellular Carcinoma
A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy
A study to describe real-world treatment patterns and overall survival in advanced liver cancer participants who received second or third line nivolumab therapy
- Trial name
- NCT04161911
- Where
- United States
- Volunteers
- 1,426 people
- Sponsor
- Bristol-Myers Squibb
Cancer
Clinical Study of Pan-cancer DNA Methylation Test in Plasma
We intend to establish an efficient method for plasma cfDNA extraction and Bisulfite transformation to facilitate the detection of DNA methylation status using multiplex fluorescence PCR.
- Trial name
- NCT05685524
- Testing
- DNA methylation test
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Wuhan Ammunition Life-tech Co., Ltd
HCC, Hepatocellular Carcinoma
LifePearl-Doxo Pharmacokinetic (PK) Study
The primary purpose of the study is to evaluate the pharmacokinetic profile, safety, and efficacy of LifePearl™ microspheres loaded with Doxorubicin in the treatment of unresectable HCC.
- Trial name
- NCT02548780
- Testing
- Chemoembolization, Pharmacokinetics
- Where
- 3 sites in Greece, Spain and 1 more
- Volunteers
- 15 people
- Sponsor
- Terumo Europe N.V.
Melanoma, Carcinoma, Hepatocellular
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386 in combination with pembrolizumab in participants with previously treated selected solid tumors, and to determine the recommended Phase 2…
- Conditions
- Melanoma, Carcinoma, Hepatocellular, Colorectal Neoplasms
- Trial name
- NCT05091346
- Testing
- E7386, Pembrolizumab, Lenvatinib
- Where
- 32 sites in United States, Japan and 2 more
- Volunteers
- 89 people
- Sponsor
- Eisai Inc.
Solid Tumor, Cancer
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or the recommended fixed dose of the combinations of mogamulizumab and nivolumab in subjects with locally…
- Conditions
- Solid Tumor, Cancer, Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT02705105
- Testing
- Mogamulizumab + Nivolumab
- Where
- 15 sites in United States
- Volunteers
- 114 people
- Sponsor
- Kyowa Kirin, Inc.
Advanced Liver Cancer
Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer
This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody for advanced liver cancer.
- Trial name
- NCT03146637
- Testing
- Activated CIK, CIK
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
Primary Hepatocellular Carcinoma
Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma
VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 injection.This study will be conducted in combination with camrelizumab in patients with advanced advanced primary hepatocellular carcinoma who have received at least one…
- Trial name
- NCT06124001
- Testing
- Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), camrelizumab for Injection
- Volunteers
- 36 people
- Sponsor
- CNBG-Virogin Biotech (Shanghai) Ltd.
Hepatocellular Carcinoma
Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
The study is designed to demonstrate that axitinib plus best supportive care is superior to placebo plus best supportive care in prolonging survival in patients with advanced hepatocellular carcinoma.
- Trial name
- NCT01210495
- Testing
- Axitinib (AG-013736), Best Supportive Care
- Where
- 77 sites in United States, Belgium and 11 more
- Volunteers
- 224 people
- Sponsor
- Pfizer
Hepatocellular Cancer, Liver Cancer
Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of BGB-B2033 monotherapy in adults with hepatocellular carcinoma who have previously been treated with anti-programmed cell death protein 1 (PD-1)/programmed…
- Conditions
- Hepatocellular Cancer, Liver Cancer, Hepatocellular Carcinoma
- Trial name
- NCT07911683
- Testing
- BGB-B2033
- Volunteers
- 100 people
- Sponsor
- BeOne Medicines
Carcinoma, Hepatocellular
Real-World Lenvatinib Sequencing in Unresectable Hepatocellular Carcinoma (uHCC)
This observational study will use existing real-world data from routine clinical care to describe patients with uHCC who received lenvatinib.
- Trial name
- NCT07849660
- Testing
- Lenvatinib
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- Eisai Inc.
Advanced Hepatocellular Carcinoma
A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of TAC-101 after Transcatheter Arterial Chemoembolization (TACE) in patients with advanced, unresectable hepatocellular carcinoma (HCC) who are being scheduled for…
- Trial name
- NCT00756782
- Testing
- TAC-101
- Sponsor
- Taiho Oncology, Inc.
Advanced Malignancies, Metastatic Cancer
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
- Trial name
- NCT03126110
- Testing
- INCAGN01876, Nivolumab, Ipilimumab
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 145 people
- Sponsor
- Incyte Biosciences International Sàrl
Lesions of the Liver
Study Investigating the Effect of E7337 on Tumor Like Lesions in Computed Tomography (CT) of the Liver
This is a multicenter, randomized, open-label study to investigate the superiority of the contrast enhancement effect of E7337 on tumor-like lesions in the Dynamic CT of the liver.
- Trial name
- NCT00280410
- Testing
- E7337
- Where
- 14 sites in Japan
- Volunteers
- 192 people
- Sponsor
- Eisai Inc.
Liver Neoplasms
Feasibility and Safety of Augmented Reality (AR) in Liver Tumor Surgery
The purpose of the trial is to evaluate a computer-based Augmented Reality System intended to help surgeons perform keyhole surgery (laparoscopy) for the removal of liver tumors more efficiently and with greater patient safety.
- Trial name
- NCT07630610
- Testing
- Augmented reality guided liver tumor surgery, Augmented reality (AR) guided liver tumor surgery
- Volunteers
- 6 people
- Sponsor
- Navari Surgical AB